back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-09-23 14:06 Tx date 2024-09-20 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: IBI Trust Management (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
$42,666
+177,777 vol $0.24 each |
1,405,554 | |
| Filed 2024-09-23 14:05 Tx date 2024-09-20 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-177,777 vol |
177,779 | |
| Filed 2024-09-23 09:54 Tx date 2024-09-16 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-177,777 vol |
||
| Filed 2024-09-23 09:54 Tx date 2024-09-16 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: IBI Trust Management (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
$42,666
+177,777 vol $0.24 each |
||
| Filed 2024-09-20 20:06 Tx date 2024-09-16 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: IBI Trust Management (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
$42,666
+177,777 vol $0.24 each |
||
| Filed 2024-09-20 20:06 Tx date 2024-09-16 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-177,777 vol |
||
| Filed 2024-09-20 20:06 Tx date 2024-09-16 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: IBI Trust Management (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
$42,666
+177,777 vol $0.24 each |
1,405,554 | |
| Filed 2024-09-20 20:06 Tx date 2024-09-16 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-177,777 vol |
177,779 | |
| Filed 2024-03-28 10:28 Tx date 2024-03-25 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: IBI Trust Management (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
+1,050,000 vol |
1,227,777 | |
| Filed 2024-03-28 10:28 Tx date 2024-03-25 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: IBI Trust Management (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
+177,777 vol |
177,777 | |
| Filed 2024-03-28 10:27 Tx date 2019-09-13 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: IBI Trust Management (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-28 10:27 Tx date 2024-03-25 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-1,050,000 vol |
355,556 | |
| Filed 2024-03-28 10:26 Tx date 2024-03-25 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-177,777 vol |
1,405,556 | |
| Filed 2024-03-18 11:58 Tx date 2024-03-14 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+1,050,000 vol |
1,583,333 | |
| Filed 2024-03-18 11:57 Tx date 2024-03-14 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+533,333 vol |
533,333 | |
| Filed 2024-03-18 11:57 Tx date 2019-09-13 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-08-15 15:58 Tx date 2023-08-11 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+700,000 vol |
3,200,000 | |
| Filed 2022-06-22 20:21 Tx date 2022-06-15 |
$ENER
NurExone Biologic Inc. (formerly, EnerSpar Corp.) |
Mayron, Ron
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
129,200 | ||
| Filed 2022-06-22 18:08 Tx date 2022-06-15 |
$ENER
NurExone Biologic Inc. (formerly, EnerSpar Corp.) |
Mayron, Ron
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
680,000 | ||
| Filed 2021-09-05 05:45 Tx date 2021-09-02 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$295,000
+500,000 vol $0.59 each |
2,500,000 | |
| Filed 2020-06-17 08:42 Tx date 2020-06-11 |
$INNO
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
2,000,000 | |
| Filed 2019-10-06 11:03 Tx date 2019-09-25 |
$
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+4,410,000 vol |
5,160,000 | |
| Filed 2019-10-06 03:48 Tx date 2019-09-13 |
$
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
1,750,000 | ||
| Filed 2019-09-22 17:15 Tx date 2019-09-13 |
$
InnoCan Pharma Corporation |
Mayron, Ron
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
750,000 |